Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

One cheerleader is rewriting what determination looks like by pushing boundaries on the mat while managing a chronic sleep ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

Of the patients across the two Phase III studies, more than 95% enrolled in the ongoing long-term extension (LTE) study.

The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...